EP1311237A2 - Utilisation de 2,4-diphosphoglycerate cyclique (cdgp) et/ou de derives dans des formulations cosmetiques et dermatologiques - Google Patents

Utilisation de 2,4-diphosphoglycerate cyclique (cdgp) et/ou de derives dans des formulations cosmetiques et dermatologiques

Info

Publication number
EP1311237A2
EP1311237A2 EP01976086A EP01976086A EP1311237A2 EP 1311237 A2 EP1311237 A2 EP 1311237A2 EP 01976086 A EP01976086 A EP 01976086A EP 01976086 A EP01976086 A EP 01976086A EP 1311237 A2 EP1311237 A2 EP 1311237A2
Authority
EP
European Patent Office
Prior art keywords
compounds
formula
formulation according
human skin
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01976086A
Other languages
German (de)
English (en)
Inventor
Thomas Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bitop Gesellschaft fur Biotechnische Optimierung mbH
Original Assignee
Bitop Gesellschaft fur Biotechnische Optimierung mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bitop Gesellschaft fur Biotechnische Optimierung mbH filed Critical Bitop Gesellschaft fur Biotechnische Optimierung mbH
Publication of EP1311237A2 publication Critical patent/EP1311237A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/08—Preparations containing skin colorants, e.g. pigments for cheeks, e.g. rouge
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners

Definitions

  • cyclic 2.4 diphosphoglycerate cDGP
  • cDGP cyclic 2.4 diphosphoglycerate
  • the invention relates to the use of one or more chemical compounds selected from the compounds of the formulas Ia (cyclic diphosphoglycerate) in cosmetic and dermatological formulations.
  • the invention relates e.g. the production of a cosmetic or dermatological formulation for protecting and stabilizing human skin cells and their organic components, such as Proteins, enzymes, membranes, nucleic acids or antioxidants.
  • the invention includes the use of physiologically compatible salts of the compounds Ia and Ib, the stereoisomeric forms of the compounds of the formulas Ia and Ib and derivatives of these compounds (for example esters) for use in cosmetic and dermatological formulations. Due to their origin from extremophilic microorganisms, which effectively protect themselves by the production of new compatible solutes such as cyclic diphosphoglycerate from environmental stress situations such as UV radiation, heat, radicals, cold, drought or osmotic or chemical stress, and only survive in this way, these substances represent a completely new way of protecting organisms and their components from damaging environmental influences.
  • the cell's own repair systems DNA repair after UV damage, induction and stabilization of the chaperon proteins for refolding (partially) denatured proteins and enzymes
  • DNA repair after UV damage, induction and stabilization of the chaperon proteins for refolding (partially) denatured proteins and enzymes can be stabilized and activated for the first time using cyclic diphosphoglycerate.
  • the maintenance of the cell's antioxidative potential protein and DNA damage by free radicals, lipid oxidation of the cell membranes is ensured for the first time by cyclic diphosphoglycerate.
  • cyclic diphosphoglycerates pass through several skin layers into the interior of the target cells and, as co-solvents or penetration enhancers, can bring other active ingredients from the cosmetic formulation (e.g. proteins, enzymes, vitamins, antioxidants) to their actual destination.
  • active ingredients e.g. proteins, enzymes, vitamins, antioxidants
  • Cyclic diphosphoglycerate Due to its chemical structure, cyclic diphosphoglycerate is compatible with the majority of the usual cosmetic basic formulations, and further modifications to the suitable form of application are possible by appropriate modifications of the functional side chains. Cyclic diphosphoglycerate is moisturizing due to the large number of hydroxyl groups and gives a pleasant feeling on the skin.
  • Compatible solutes act as natural solvents in extremophilic microorganisms and stabilize enzymes, proteins and other cell components by generating a more native, globular state that not only protects the proteins from proteolysis, but also keeps them in a more compact and active state.
  • Cyclic is used as a co-solvent or penetration enhancer for cosmetic active ingredients
  • Diphosphoglycerate can be used in a wide range, particularly with regard to the possible derivatization of individual functional groups.
  • the invention thus relates to the use of cyclic diphosphoglycerate as an additive and active ingredient with a completely new mode of action in cosmetic and dermatological preparations and products.
  • UV filters Today's skin and sunscreen products include two classes of UV filters. Physically effective UV filters consist of inorganic compounds (e.g. titanium dioxide) that reflect the light that hits the skin. Chemically acting organic molecules absorb UV light of the wavelengths that are responsible for the formation of erythema (sunburn) (primarily 295 to 323 nm with a maximum at 308 nm).
  • inorganic compounds e.g. titanium dioxide
  • chemically acting organic molecules absorb UV light of the wavelengths that are responsible for the formation of erythema (sunburn) (primarily 295 to 323 nm with a maximum at 308 nm).
  • radical scavengers and antioxidants are used as additives in cosmetic formulations to protect against oxidative stress, which is caused by environmental influences (UV radiation, smoke, chemical substances) but also by the cell's own activities.
  • the range of active ingredients covers both water-soluble radical scavengers (e.g. ascorbic acid), which act in the interior of the liquid, and fat-soluble antioxidants (e.g. retionol palmitate or ⁇ -tocopherol), which Membrane structures take effect. It is rarely taken into account that with topical applications of these active ingredients, at most 3% reach a deeper skin layer and the rest remains ineffective on the skin surface.
  • Hyperthermophiles are very unusual microorganisms because they grow optimally at temperatures (60-110 ° C), which would lead to massive damage to cellular structures in mesophilic ("normal") organisms.
  • a large amount of research has therefore been carried out to determine the Identify biochemical components that lead to the remarkable thermal, chemical and physical stabilization of cell structures, with the focus of the research work on the isolation of thermostable enzymes, since numerous enzymatically catalyzed industrial processes take place under extreme environmental conditions and suitable biocatalysts are sought.
  • many enzymes from hyperthermophilic microorganisms are stable even at high temperatures, this does not generally apply to the cellular structures of thermo- and hyperthermophilic organisms.
  • thermophilic microorganisms Low molecular weight organic substances (compatible solutes, "hypersolutes") in the intracellular milieu make a significant contribution to the high temperature stability of cell structures.
  • Various novel hypersolutes have been identified in hyperthermophilic microorganisms in recent years. In some cases, the contribution of these compounds to Protection of cellular structures - especially enzymes - against heat and drought has already been impressively demonstrated, bitop has developed technologies for the production of compatible solutes from thermophilic microorganisms.
  • the human skin is an organ that protects the body from external influences with various types of specialized cell types - the keratinocytes, melanocytes, Langerhans cells, Merkel cells and embedded sensory cells.
  • the external physical influences include thermal and mechanical influences as well as the effect of radiation, e.g. UV, VIS, and IR radiation, count.
  • External chemical influences are to be understood in particular as the effects of toxins, allergens and substances which bind to the deoxyribonucleic acid.
  • the external biological influences include the effects of foreign organisms and their metabolic products.
  • Sunburn erythema solare
  • UV-A radiation has a comparatively minor influence on its formation.
  • Sunburn can range from a light tint to a severe burn with blistering. Since these episodes no earlier than 4-6 h after the radiation occurs, it is too late for countermeasures. Multiple sunburns - especially in childhood - significantly increase the risk of skin cancer.
  • the causes for this are damage, in particular the nucleic acids of human skin cells and a faulty repair of the damaged deoxyribonucleic acid in the cell nucleus, as well as probably the immunosuppressive effect of UV radiation, ie the weakening of the immune response by UV radiation.
  • Excessive UV-A and UV-B exposure contributes to skin aging or light aging, for example in the form of structural changes in the connective tissue (actinic elastosis).
  • Excessive UV-B exposure is the main cause of chronic skin changes.
  • Each tissue has an antioxidative potential (AOP) made up of enzymatic and non-enzymatic antioxidants, which keep the content of prooxidants below a limit value in unstressed cells, which is harmless to the healthy cell. If these natural antioxidants are inactivated or denatured, the skin's resistance and regeneration ability is significantly reduced.
  • AOP antioxidative potential
  • Extremophilic microorganisms thermophiles and hyperthermophiles protect themselves from thermal stress through the formation of cyclic diphosphoglycerate. In the presence of these substances it is therefore possible for these microbial organisms to exist under the prevailing extreme conditions, since cyclic diphosphoglycerate stabilizes the metabolism and the essential organic components and protects against damage.
  • cyclic diphosphoglycerate also shows the stabilizing effects on human skin and thus represents an ideal active ingredient and additive for cosmetic and dermatological preparations.
  • Cyclic diphosphoglycerate thus represents a universally applicable and completely new protective principle in cosmetics and dermatology.
  • the above-mentioned problem is selected by using one or more compounds from the compounds of the formulas la (cyclic diphosphoglycerate) in cosmetic and dermatological formulations solved.
  • the invention relates to Use of one or more compounds selected from the compounds of the formula Ia (cyclic diphosphoglycerate),
  • physiologically tolerable salts of the compound la the stereoisomeric forms of the compounds of the formula la and derivatives for the preparation of a cosmetic or dermatological formulation for protecting and stabilizing human skin cells and their organic constituents, e.g. Proteins, enzymes, membranes, nucleic acids or antioxidants.
  • Possible salts are the alkali and alkaline earth salts, but especially the Na and K salts.
  • the esters which can be used are the esters of physiologically acceptable alcohols, in particular C 1 -C 4 alcohols, such as methanol, ethanol, propanols or butanols.
  • the invention relates in particular to the use of one or more compounds selected from the compounds of the formula Ia, the physiologically tolerable salts of the compounds of the formula Ia and the stereoisomeric forms of the compounds of the formula Ia for the production of a cosmetic or dermatological formulation for protecting and stabilizing the human skin cells and their organic components such as proteins, enzymes, membranes, nucleic acids, antioxidants etc. from physical, chemical and biological influences such as from radiation (UV, IR, VIS radiation), from denaturing substances, from temperature or from cold.
  • the present invention describes this principle of protection for the first time.
  • the possible uses are very diverse and can only be described by way of example within the scope of the invention. However, the invention is not intended to be limited by giving examples.
  • Membranes represent the natural barrier of cells and cell organelles to the surrounding medium. The membranes make it possible to ensure a constant internal environment in the individual cells or cell components. Biological membranes are multi-component systems that generally consist of lipids, cholesterol and proteins. The exact composition of individual membranes is subject to varying fluctuations depending on their origin. However, elementary components of membranes are lipids and proteins.
  • Lipids can be divided into the so-called “simple” lipids such as fats and waxes and “complex” lipids.
  • phosphoric acid diesters in which the glycerol residue generally is condensed with saturated (R1) and unsaturated (R2) fatty acids.
  • the phosphoric acid residue is additionally condensed with a component of alcoholic structure such as inositol or ethanolamine (R3).
  • glycerophospholipids Due to their ambivalent structure with a hydrophilic phosphate residue and lipophilic fatty acid residues, glycerophospholipids are able to in water Solution to form aggregates (eg double layers or micelles) in which the only hydrophilic phosphate residue comes into contact with the aqueous phase. This structure is also found in the form of closed lamellar vesicles, the so-called liposomes.
  • the following figure shows an example of the group of lipids with two phosphodiester groups, the so-called diphosphatidylglycerols (cardiolipins):
  • DIP Determination of a phosphate anion: stabilization of protein side chains via ionic and van der Waals interactions. Furthermore DIP is characterized by the following features:
  • cDPG is the cell's natural solvent.
  • biogenic substances have to be solubilized. No data on the toxicity of the substance are available to date.
  • the intracellular concentration of cDPG within the cell is over 300 mM, so that a high level of biocompatibility can also be expected here!
  • cDPG has very good protective properties in the thermally induced denaturation of enzymes, some of which are better in comparison to other compatible solutes.
  • LDH freezing protein solutions
  • the commercial application of the invention is in the entire field of cosmetic and dermatological products and as research reagents in the field of cosmetic and dermatological development.
  • the cosmetic and dermatological formulations are prepared by one or more compounds of the formula la (cyclic diphosphoglycerate), the physiologically tolerable salts of the compounds of the formula la, the stereoisomeric forms of the compound of the formula la or derivatives, optionally with auxiliaries and / or carriers be brought into a suitable formulation.
  • the auxiliaries and carriers come from the group of carriers, preservatives and other customary auxiliaries.
  • the compounds of the formula la (cyclic diphosphoglycerate) contained in cosmetic and dermatological formulations, the physiologically tolerable salts of the compounds of the formula la and the stereoisomeric forms of the compounds of the formula la are used externally.
  • solutions, suspensions, emulsions, pastes, ointments, gels, creams, lotions, powders, soaps, surfactant-containing cleaning preparations, oils and sprays can be added to the formulations.
  • Preferred additives come from the group of preservatives, antioxidants, stabilizers, solubilizers, vitamins, colorants and odor improvers.
  • ointments, pastes, creams and gels can contain the usual carriers, e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc and zinc oxide or mixtures of these substances.
  • carriers e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc and zinc oxide or mixtures of these substances.
  • powders and sprays can contain the usual blowing agents, for example chlorofluorocarbons, propane / butane or dimethyl ether, in addition to the customary carriers.
  • solutions and emulsions can additionally contain the customary carriers, such as solvents, solubilizers and emulsifiers or oils.
  • suspensions can contain additional carriers such as e.g. Contain water or ethanol.
  • the proportion of the compound of the formula Ia (cyclic diphosphoglycerate), the physiologically tolerable salts of the compounds IA, and the stereoisomeric forms of the compounds of the formula IA cosmetic and dermatological formulations is preferably from 0.0001 to 50% by weight, particularly preferably from 0.001 to 10 % By weight based on the entire cosmetic formulation.
  • cyclic diphosphoglycerate supports e.g. through the proven stabilization against thermal protein denaturation and inactivation the cell's own antioxidative potential. Damage caused by radicals is thus counteracted. Due to the proven DNA protection of compatible solutes and their protein-stabilizing effect, the use of cyclic diphosphoglycerate according to the invention represents a new type of active sun protection (e.g. UV and IR radiation) in cosmetics and dermatology.
  • active sun protection e.g. UV and IR radiation
  • a lotion (O / W) according to the invention containing cyclic diphosphoglycerate is produced from the following components:
  • a cream (O / W) according to the invention containing cyclic diphosphoglycerate is produced from the following components:
  • An inventive liposome-containing gel containing cyclic diphosphoglycerate is produced from the following components:
  • An inventive gel (O / W) containing cyclic diphosphoglycerate is produced from the following components:
  • a sunscreen emulsion according to the invention containing cyclic diphosphoglycerate is produced from the following components:
  • Example sun lotion 0.05% propyl hydroxybenzoate or 0.15% methyl 4-hydroxybenzoate can be used as a preservative.
  • Example sun lotion 0.05% propyl hydroxybenzoate or 0.15% methyl 4-hydroxybenzoate can be used as a preservative.
  • An emulsifier-free sun lotion SPF 30 (W / O) containing cyclic diphosphoglycerate is produced from the following components:
  • a hair tonic according to the invention containing cyclic diphosphoglycerate is produced from the following components:
  • a spray formulation according to the invention containing cyclic diphosphoglycerate is produced from the following components:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'incorporation de 2,4-diphosphoglycérate cyclique (cDGP), substance de faible poids moléculaire (soluté compatible), obtenue à partir de micro-organismes extrêmophiles et/ou de dérivés de ce composé, p. ex. un acide, un sel ou un ester, dans des formulations cosmétiques ou dermatologiques destinées à protéger la peau des effets de l'environnement et à augmenter la capacité de régénération de la peau. Selon ladite invention, la 2,4-diphosphoglycérate cyclique intervient dans la protection cellulaire active du piège à radicaux et des antioxydants propres aux cellules, de l'ADN, des membranes cellulaires et d'autres compartiments cellulaires, en les protégeant contre des effets de l'environnement tels qu'un rayonnement UV, un rayonnement IR et des agressions de l'environnement (thermiques, chimiques et physiques). Ce soluté compatible peut servir de co-solvant et d'agent pénétrant à d'autres substances actives additionnées à la formulation cosmétique, de manière à stabiliser ces substances dans la formulation cosmétique et à les faire pénétrer de manière active dans des couches cutanées profondes.
EP01976086A 2000-08-18 2001-08-16 Utilisation de 2,4-diphosphoglycerate cyclique (cdgp) et/ou de derives dans des formulations cosmetiques et dermatologiques Withdrawn EP1311237A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10040931A DE10040931A1 (de) 2000-08-18 2000-08-18 Verwendung von cyclischem 2,4 Diphosphoglycerat (cDGP) und/oder Derivaten in kosmetischen und dermatologischen Formulierungen
DE10040931 2000-08-18
PCT/EP2001/009443 WO2002015866A2 (fr) 2000-08-18 2001-08-16 Utilisation de 2,4-diphosphoglycerate cyclique (cdgp) et/ou de derives dans des formulations cosmetiques et dermatologiques

Publications (1)

Publication Number Publication Date
EP1311237A2 true EP1311237A2 (fr) 2003-05-21

Family

ID=7653223

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01976086A Withdrawn EP1311237A2 (fr) 2000-08-18 2001-08-16 Utilisation de 2,4-diphosphoglycerate cyclique (cdgp) et/ou de derives dans des formulations cosmetiques et dermatologiques

Country Status (6)

Country Link
US (1) US20040097543A1 (fr)
EP (1) EP1311237A2 (fr)
JP (1) JP2004506674A (fr)
AU (1) AU2001295468A1 (fr)
DE (1) DE10040931A1 (fr)
WO (1) WO2002015866A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10330243A1 (de) * 2003-07-03 2005-01-20 bitop Aktiengesellschaft für biotechnische Optimierung Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von Arzneimitteln zur äusserlichen Behandlung der Neurodermitis
DE102004049062A1 (de) * 2004-03-30 2005-10-13 bitop Aktiengesellschaft für biotechnische Optimierung Topische Zubereitung zur Anwendung auf der Haut enthaltend natürliches Öl der Nachtkerze (Oenothera biennis) (=Oleum Oenothera) und Osmolyte aus extremophilen Mikroorganismen
DE102005056538A1 (de) * 2005-11-28 2007-05-31 Merz Pharma Gmbh & Co. Kgaa Zusammensetzungen, enthaltend Proteine zum Transfer / Recycling strukturell veränderter Lipide aus Biomembranen, sowie deren Anwendungen
JP6094826B2 (ja) * 2014-07-16 2017-03-15 トヨタ自動車株式会社 非水電解液二次電池とその製造方法および非水電解液

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6296857B1 (en) * 1998-09-23 2001-10-02 Beiersdorf Aktiengesellschaft Cosmetic or dermatological preparations comprising oligopeptides for lightening the skin of age marks and/or for preventing tanning of the skin, in particular tanning of the skin caused by UV radiation
ATE247981T1 (de) * 1999-06-12 2003-09-15 Bitop Ag Proteinenthaltende pharmazeutische zubereitung
ES2233630T3 (es) * 2000-04-12 2005-06-16 Bitop Aktiengesellschaft Fur Biotechnische Optimierung Uso de solutos compatibles como sustancias con propiedades barredoras de radicales.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0215866A2 *

Also Published As

Publication number Publication date
WO2002015866A2 (fr) 2002-02-28
WO2002015866A3 (fr) 2002-06-06
AU2001295468A1 (en) 2002-03-04
JP2004506674A (ja) 2004-03-04
US20040097543A1 (en) 2004-05-20
DE10040931A1 (de) 2002-03-07

Similar Documents

Publication Publication Date Title
EP1311238B1 (fr) Utilisation de di-sucres de phosphate d'alcool pour proteger les cellules de la peau humaine contre les radiations uv et/ou ir
DE4228455A1 (de) Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Thiolen und/oder Thiolderivaten
EP1100457B1 (fr) Utilisation d'ectoine ou de derives d'ectoine dans des formulations cosmetiques
WO2005094771A1 (fr) Preparation topique cutanee contenant des essences naturelles d'onagre bisannuelle (oenothera biennis) (=oleum oenotherae) et osmolytes issus de micro-organismes extremophiles
WO2000007558A1 (fr) Utilisation d'ectoine ou de derives d'ectoine dans des formulations cosmetiques
DE10136077A1 (de) Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin und/oder Kreatininderivaten mit Kreatin und/oder seinen Derivaten
KR101981696B1 (ko) 천연 복합 추출물을 유효 성분으로 포함하는 피부 보습용 미스트 조성물
WO2002015867A1 (fr) UTILISATION DE β-MANNOSYLGLYCERATE ET DE SES DERIVES DANS DES FORMULATIONS COSMETIQUES ET DERMATOLOGIQUES
KR101910962B1 (ko) 세라마이드 액정 조성물 및 이의 제조방법
EP1414401A1 (fr) Utilisation de creatinine et/ou de derives de la creatinine dans des preparations cosmetiques ou dermatologiques
EP1311237A2 (fr) Utilisation de 2,4-diphosphoglycerate cyclique (cdgp) et/ou de derives dans des formulations cosmetiques et dermatologiques
DE60106014T2 (de) Verwendung von n,n'-dibenzylethylendiamindiessigsäurederivaten zum schutz gegen verschmutzung
KR102278167B1 (ko) 지질산화 방지, 자외선에 의한 손상 피부 개선 및 피부 진정 효과가 우수한 화장료 조성물
DE10055706A1 (de) Verwendung von Di-Glycerinphosphat (DGP) und/oder Derivaten in kosmetischen und dermatologischen Formulierungen
KR102087976B1 (ko) 물푸레나무 추출물을 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물
DE10040932A1 (de) Verwendung von Di-myo-inositolphosphat (DIP) und/oder Derivaten in kosmetischen und dermatologischen Formulierungen
KR102608587B1 (ko) 능소화추출물을 함유한 화장료 조성물 및 이의 제조방법
EP2384738B1 (fr) Utilisation d'esters salicyliques pour le masquage d'odeur de produits de dégradation de l'urée
WO2016169798A1 (fr) Utilisation de l'hibifoline contre le vieillissement de la peau
KR100569812B1 (ko) 항자극 복합물 및 이를 함유하는 피부 보호용 화장료 조성물
KR20220060036A (ko) 케라틴을 함유하는 항염증 조성물
KR20230086211A (ko) 보검 선인장 줄기 추출물 및 테킬라 용설란 잎 추출물을 포함하는 화장료 조성물
KR20230065652A (ko) 오이, 알로에베라잎 및 보검선인장열매의 혼합추출물을 유효성분으로 함유하는 화장료 조성물
WO2008006485A1 (fr) Préparations cosmétiques ou dermatologiques contenant de l'acide folique et un ou plusieurs polyols
DE102011085535A1 (de) Kosmetische oder dermatologische Wasser–in–Öl-Emulsionen mit einem Gehalt anHarnstoff und Polyglyceryl-4 Diisostearat/Polyhydroxystearat/Sebacat.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030312

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20061219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070301